undamentalytics Newsletter
Sign in

CG Oncology, Inc. income statement

In fiscal 2025, CG Oncology, Inc. reported revenue of $4.0m, up 254.7% on the year before, operating income of −$191m (a -4722.1% margin) and net income of −$161m, or −$2.08 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0146
Research and development4682117156
General and administrative10347491
Operating income−55−115−191−253
Income tax00−0—
Net income−49−88−161−224
Diluted EPS−$1.04−$1.41−$2.08−$2.72
Diluted shares (average)65m62m77m82m
EBITDA−55−115−189−250

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CGON vs FATECGON vs HCWBCGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from CG Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to CG Oncology, Inc.